Serotonin News and Research

Latest Serotonin News and Research

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Neurocrine Biosciences, Inc. announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

6 Apr 2011

Study: Antidepressants can thicken arteries and lead to heart disease

Antidepressant use has been linked to thicker arteries, possibly contributing to the risk of heart disease and stroke, in a study of twin veterans. The data is being presented Tuesday, April 5 at the American College of Cardiology meeting in New Orleans.

4 Apr 2011

Antidepressants may increase heart attack or stroke risk in men: Study

...

3 Apr 2011

Early recognition and treatment can control obsessive-compulsive manifestation

Obsessive-compulsive disorder is often diagnosed too late in children and adolescents. In the current issue of Deutsches Ärzteblatt International, Susanne Walitza and her colleagues point out that appropriate early recognition and treatment can positively affect the course of the disease.

1 Apr 2011

Panax ginseng, saffron and yohimbine can boost human sexual function

Looking to spice up your sex life? Try adding ginseng and saffron to your diet. Both are proven performance boosters, according to a new scientific review of natural aphrodisiacs conducted by University of Guelph researchers.

28 Mar 2011

Serotonin influences sexual preference: Study

Researchers from Beijing's National Institute of Biological Sciences, China have found a chemical in the brain controls sexual preference in mice. The study published in the journal Nature said that male mice bred without serotonin lose their preference for females. This is the first study that shows that a neurotransmitter plays a role in sexual preference in mammals. However it is still a long way before similar conclusions can be drawn for humans the experts believe.

24 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Researchers discover a type of 'cellular bilingualism' in brain

A team of researchers from the University of Montreal and McGill University have discovered a type of "cellular bilingualism" - a phenomenon that allows a single neuron to use two different methods of communication to exchange information.

18 Mar 2011

Study investigates physiological changes within brain due to Prozac treatment

Selective serotonin reuptake inhibitors (SSRI) such as Prozac are regularly used to treat severe anxiety and depression. They work by immediately increasing the amount of serotonin in the brain and by causing long term changes in brain function. However it can take weeks of treatment before a patient feels any effect and both beneficial effects and side effects can persist after treatment is stopped.

16 Mar 2011

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.

14 Mar 2011

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.

14 Mar 2011

Prolonged exposure to antidepressants can induce tardive dysphoria

In the current issue of Psychotherapy and Psychosomatics a new important side effect of antidepressant drugs is described: tardive dysphoria.

9 Mar 2011

UH conducts first ever pilot study to test heat therapy for treatment of PE

University Hospitals Case Medical Center is conducting the first ever pilot study to test a new procedure using "heat therapy" or local radiofrequency energy to treat premature ejaculation.

9 Mar 2011

Scientists find link between ADHD and bipolar disorders with regard to rapid mood swings

Thanks in part to a Norwegian research biobank, researchers have generated important new insight into ADHD and how the condition manifests itself. Among other things, they have found that there is some overlap between ADHD and bipolar disorders with regard to rapid mood swings.

2 Mar 2011

Role of serotonin in autism spectrum disorders

Mouse models are yielding important clues about the nature of autism spectrum disorders, which impact an estimated one in 110 children in the U.S. In labs at the UT Health Science Center San Antonio, researchers are studying strains of mice that inherently mimic the repetitive and socially impaired behaviors present in these disorders.

25 Feb 2011

Scientists suggest that lateral habenula can be a prime locus of human depression

A team of neuroscientists at Cold Spring Harbor Laboratory, Brookhaven National Laboratory and UC San Diego has collected evidence suggesting that a previously overlooked portion of the brain could be a prime locus of human depression.

24 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Mouse model could help develop new classes of antidepressant drugs

The most widely prescribed antidepressants - medicines such as Prozac, Lexapro and Paxil - work by blocking the serotonin transporter, a brain protein that normally clears away the mood-regulating chemical serotonin. Or so the current thinking goes.

21 Feb 2011

WINCS detects and measures serotonin levels in brain through deep brain stimulation

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System (WINCS) can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

16 Feb 2011

L-methylfolate in combination with antidepressant drug helps major depressive disorder patients

Data published in the January issue of Innovations in Clinical Neuroscience, www.psychiatrymmc.com, suggest when L-methylfolate, a medical food available commercially as Deplin®, and by prescription, is used for dietary management of depression in combination with an antidepressant drug at the start of depression therapy, it results in significantly more patients experiencing major improvement and more rapid improvement than antidepressant monotherapy alone.

10 Feb 2011

Serotonin News and Research

Latest Serotonin News and Research

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Study: Antidepressants can thicken arteries and lead to heart disease

Antidepressants may increase heart attack or stroke risk in men: Study

Early recognition and treatment can control obsessive-compulsive manifestation

Panax ginseng, saffron and yohimbine can boost human sexual function

Serotonin influences sexual preference: Study

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Researchers discover a type of 'cellular bilingualism' in brain

Study investigates physiological changes within brain due to Prozac treatment

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Prolonged exposure to antidepressants can induce tardive dysphoria

UH conducts first ever pilot study to test heat therapy for treatment of PE

Scientists find link between ADHD and bipolar disorders with regard to rapid mood swings

Role of serotonin in autism spectrum disorders

Scientists suggest that lateral habenula can be a prime locus of human depression

Forest Labs enters definitive merger agreement to acquire Clinical Data

Mouse model could help develop new classes of antidepressant drugs

WINCS detects and measures serotonin levels in brain through deep brain stimulation

L-methylfolate in combination with antidepressant drug helps major depressive disorder patients

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Serotonin News and Research

Latest Serotonin News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in